Related Experiment Videos
Pulmonary hypertension.
1Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts, USA.
Drugs of Today (Barcelona, Spain : 1998)
|January 27, 2004
Summary
Pulmonary hypertension, a serious disorder, has limited treatment options. Advances in understanding its causes and treatments are ongoing, but more research is needed to improve patient outcomes.
Area of Science:
- Cardiology
- Pulmonology
- Vascular Medicine
Background:
- Pulmonary hypertension (PH) arises from increased pulmonary blood flow, left-heart impedance, or pulmonary vascular resistance.
- Despite diverse etiologies, PH shares common clinical presentations and natural history.
- Current therapeutic strategies are limited, focusing on underlying cause correction and supportive care.
Purpose of the Study:
- To review the current understanding of pulmonary hypertension pathobiology and treatment.
- To highlight the limited therapeutic options and the need for further research.
Main Methods:
- Literature review of pulmonary hypertension causes, clinical presentation, natural history, and therapeutic interventions.
- Analysis of current treatment modalities including oxygen, anticoagulation, vasodilatory therapy, and transplantation.
Main Results:
- Therapeutic options for PH are limited, primarily involving correction of underlying causes, oxygen, anticoagulation for low cardiac output, and vasodilatory therapies for primary PH.
- Lung or heart-lung transplantation is the sole option for severe cases.
- Significant progress has been made in understanding PH pathobiology and treatment, yet substantial knowledge gaps persist.
Conclusions:
- Pulmonary hypertension is a complex disorder with limited effective treatments.
- Ongoing research is crucial for improving the management and outcomes for patients with pulmonary hypertension.
- Further investigation into the pathobiology and novel therapeutic approaches is essential.